RE: Delta + .25 Jun 2021 17:05
I am more interested in the comments re: the effectiveness (or not) of monoclodal antibody treatment. Hope those bods making the decision in the EMA are paying attention.
"These are, it said: increased transmissibility, stronger binding to receptors of lung cells and the POTENTIAL REDUCTION in monoclonal antibody response (which COULD REDUCE the efficacy of a lifesaving monoclonal antibody therapy given to some hospitalized Covid patients).
“If we go by the currently available evidence, Delta plus is not very different from Delta variant. It is the same Delta variant with one additional mutation. The only clinical difference, which we know till now, is that Delta plus has SOME RESISTANCE to monoclonal antibody combination therapy. And that is not a major difference as the therapy itself is INVESTIGATIONAL and FEW are ELIGIBLE for this treatment.”